

Author index

Volume 39 (1998)

-
- Arima, Y., see Miyamoto, D. 39, 89
 Ashida, N., see Machida, H. 39, 129
- Belec, L., see Mohamed, A.S. 39, 47
 Bonneze, W., see Evans, T.G. 39, 163
 Bousquet, C., see Duan, J. 39, 189
- Cordingley, M.G., see Duan, J. 39, 189
 Cotigny, S., see Mohamed, A.S. 39, 47
- De Clercq, E., see Schols, D. 39, 175
 de Jong, M.D., G.J. Galasso, B. Gazzard, P.D. Griffiths, D.A. Jabs, E.R. Kern, S.A. Spector, Summary of the II International Symposium on Cytomegalovirus 39, 141
 De Meester, I., see Schols, D. 39, 175
 Duan, J., W. Paris, P. Kibler, C. Bousquet, M. Liuzzi, M.G. Cordingley, Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice 39, 189
- Eizuru, Y., see Machida, H. 39, 129
 Endo, M., see Machida, H. 39, 129
 Endo, N., see Miyamoto, D. 39, 89
 Evans, T.G., W. Bonneze, H.R. Soucier, T. Fitzgerald, D.C. Gibbons, R.C. Reichman, Highly active antiretroviral therapy results in a decrease in CD8⁺ T cell activation and preferential reconstitution of the peripheral CD4⁺ T cell population with memory rather than naive cells 39, 163
- Fa-Ching Chen, see Zembower, D.E. 39, 81
 Fitzgerald, T., see Evans, T.G. 39, 163
 Flanagan, T.D., see Wagner, M. 39, 113
 Flavin, M.T., see Zembower, D.E. 39, 81
- Galasso, G.J., see de Jong, M.D. 39, 141
 Gazzard, B., see de Jong, M.D. 39, 141
 Gibbons, D.C., see Evans, T.G. 39, 163
 Gilquin, J., see Mohamed, A.S. 39, 47
 Granneman, G.R., see Molla, A. 39, 1
- Griffiths, P.D., see de Jong, M.D. 39, 141
 Gutmann, L., see Mohamed, A.S. 39, 47
- Hozumi, T., see Nakano, M. 39, 25
- Ida, M., see Nakano, M. 39, 25
 Ijichi, O., see Machida, H. 39, 129
- Jabs, D.A., see de Jong, M.D. 39, 141
- Kawana, T., see Nakano, M. 39, 25
 Kazatchkine, M., see Mohamed, A.S. 39, 47
 Kempf, D.J., see Molla, A. 39, 1
 Kern, E.R., see de Jong, M.D. 39, 141
 Kibler, P., see Duan, J. 39, 189
 Kitano, K., see Machida, H. 39, 129
 Korba, B.E., see Zembower, D.E. 39, 81
 Kurokawa, M., see Nakano, M. 39, 25
 Kusagaya, Y., see Miyamoto, D. 39, 89
- Lawetz, C., M. Liuzzi, The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture 39, 35
 Lin, Y.-M., see Zembower, D.E. 39, 81
 Liuzzi, M., see Duan, J. 39, 189
 Liuzzi, M., see Lawetz, C. 39, 35
- Machida, H., N. Ashida, S. Miura, M. Endo, K. Yamada, K. Kitano, Y. Yoshimura, S. Sakata, O. Ijichi, Y. Eizuru, Anti-herpesvirus activity profile of 4'-thioarabinofuranosyl purine and uracil nucleosides and activity of 1- β -D-2'-fluoro-4'-thioarabinofuranosyl guanine and 2,6-diaminopurine against clinical isolates of human cytomegalovirus 39, 129
 Matta, M., see Mohamed, A.S. 39, 47
 Miura, S., see Machida, H. 39, 129
 Miyamoto, D., Y. Kusagaya, N. Endo, A. Sometani, Seiji Takeo, T. Suzuki, Y. Arima, K. Nakajima, Yasuo Suzuki, Thujaplicin-copper chelates inhibit replication of human influenza viruses 39, 89

- Mohamed, A.S., M. Kazatchkine, C. Piketty, S. Cotigny, J. Gilquin, L. Weiss, M. Matta, L. Gutmann, L. Belec, The sequential occurrence of *pol* 215 and *pol* 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load **39**, 47
- Molla, A., G.R. Granneman, E. Sun, D.J. Kempf, Recent developments in HIV protease inhibitor therapy **39**, 1
- Morohashi, M., see Nakano, M. **39**, 25
- Nakajima, K., see Miyamoto, D. **39**, 89
- Nakano, M., M. Kurokawa, T. Hozumi, A. Saito, M. Ida, M. Morohashi, T. Namba, T. Kawana, K. Shiraki, Suppression of recurrent genital herpes simplex virus type 2 infection by *Rhus javanica* in guinea pigs **39**, 25
- Namba, T., see Nakano, M. **39**, 25
- Ohki, S., see Wagner, M. **39**, 113
- Paris, W., see Duan, J. **39**, 189
- Piketty, C., see Mohamed, A.S. **39**, 47
- Proost, P., see Schols, D. **39**, 175
- Reichman, R.C., see Evans, T.G. **39**, 163
- Robinson, W.E., Jr., L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350) **39**, 101
- Saito, A., see Nakano, M. **39**, 25
- Sakata, S., see Machida, H. **39**, 129
- Scharpé, S., see Schols, D. **39**, 175
- Schols, D., P. Proost, S. Struyf, A. Wuyts, I. De Meester, S. Scharpé, J. Van Damme, E. De Clercq, CD26-processed RANTES(3–68), but not intact RANTES, has potent anti-HIV-1 activity **39**, 175
- Seiji Takeo, see Miyamoto, D. **39**, 89
- Shiraki, K., see Nakano, M. **39**, 25
- Sometani, A., see Miyamoto, D. **39**, 89
- Soucier, H.R., see Evans, T.G. **39**, 163
- Spector, S.A., see de Jong, M.D. **39**, 141
- Struyf, S., see Schols, D. **39**, 175
- Sun, E., see Molla, A. **39**, 1
- Suzuki, T., see Miyamoto, D. **39**, 89
- Thompson, K.D., Antiviral activity of Viracea® against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus **39**, 55
- Van Damme, J., see Schols, D. **39**, 175
- Wagner, M., T.D. Flanagan, S. Ohki, Effects of anionic and nonionic polymers on fusion and binding of Sendai virus to human erythrocyte ghosts **39**, 113
- Weiss, L., see Mohamed, A.S. **39**, 47
- Wuyts, A., see Schols, D. **39**, 175
- Wyde, P.R., Respiratory syncytial virus (RSV) disease and prospects for its control **39**, 63
- Yamada, K., see Machida, H. **39**, 129
- Yasuo Suzuki, see Miyamoto, D. **39**, 89
- Yoshimura, Y., see Machida, H. **39**, 129
- Zembower, D.E., Y.-M. Lin, M.T. Flavin, Fa-Ching Chen, B.E. Korba, Robustaflavone, a potential non-nucleoside anti-hepatitis B agent **39**, 81